Predictors of heterogeneity in the first-line treatment of patients with advanced/metastatic gastric cancer in the U.S.

Background Patients with metastatic gastric cancer have a poor prognosis (5-year survival of less than 10%). This study was designed to describe the treatment patterns of patients with gastric cancer and to understand the factors associated with treatment choices to inform evidence-based care.